NCT00346684已完成2 期
Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •lymphocyte predominant Hodgkin´s lymphoma (histologically proven)
- •clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR > 50mm/h)
- •age 18 - 75
- •WHO performance status 0-3
- •normal organ function
- •written informed consent
排除标准
- •classical Hodgkin´s lymphoma
- •composite lymphoma
- •leucocytes < 3000/µl
- •thrombocytes < 100.000/µl
研究者
研究点 (2)
Loading locations...
相似试验
终止
3 期
R-ABVD vs ABVD-RT in Early Stage Hodgkin's LymphomaHodgkin LymphomaNCT00992030Fondazione Michelangelo112
招募中
3 期
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)Hodgkin Lymphoma, AdultNCT04638790State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia300
已完成
1 期
Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin LymphomaHigh Grade Lymphomas CD20 PositiveNCT01958996Poitiers University Hospital27
招募中
2 期
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialNodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell LymphomaNCT05886036National Cancer Institute (NCI)70
Unknown
4 期
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PETHodgkin DiseaseNCT00188149University Hospital Carl Gustav Carus300